113 related articles for article (PubMed ID: 15578684)
1. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
2. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
Saatee S; Afrakhteh M; Sadrolhefazi B
Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
[No Abstract] [Full Text] [Related]
3. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
7. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
9. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
11. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Gabos Z; Sinha R; Hanson J; Chauhan N; Hugh J; Mackey JR; Abdulkarim B
J Clin Oncol; 2006 Dec; 24(36):5658-63. PubMed ID: 17102066
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary metastases of breast cancer. When is resection indicated?
Welter S; Jacobs J; Krbek T; Tötsch M; Stamatis G
Eur J Cardiothorac Surg; 2008 Dec; 34(6):1228-34. PubMed ID: 18824371
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
16. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Hameed O; Chhieng DC; Adams AL
Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
20. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
Van Mieghem T; Leunen K; Pochet N; De Moor B; De Smet F; Amant F; Berteloot P; Timmerman D; Vanden Bempt I; Drijkoningen R; Wildiers H; Paridaens R; Smeets A; Hendrickx W; Van Limbergen E; Christiaens MR; Vergote I; Neven P
Breast Cancer Res Treat; 2007 Nov; 106(1):127-33. PubMed ID: 17211534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
